Candriam SCA’s Revance Therapeutics, Inc. RVNC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-299,039
| Closed | -$909K | – | 720 |
|
|
2024
Q4 | $909K | Buy |
+299,039
| New | +$1.3M | 0.01% | 592 |
|
|
2020
Q3 | – | Sell |
-45,000
| Closed | -$1.1M | – | 831 |
|
|
2020
Q2 | $1.1M | Sell |
45,000
-170,000
| -79% | -$3.36M | 0.01% | 585 |
|
|
2020
Q1 | $3.41M | Hold |
215,000
| – | – | 0.04% | 439 |
|
|
2019
Q4 | $3.49M | Sell |
215,000
-22,000
| -9% | -$341K | 0.04% | 453 |
|
|
2019
Q3 | $3.08M | Hold |
237,000
| – | – | 0.04% | 411 |
|
|
2019
Q2 | $3.06M | Hold |
237,000
| – | – | 0.04% | 433 |
|
|
2019
Q1 | $3.73M | Hold |
237,000
| – | – | 0.05% | 375 |
|
|
2018
Q4 | $4.77M | Buy |
237,000
+66,000
| +39% | +$1.45M | 0.07% | 291 |
|
|
2018
Q3 | $4.25M | Hold |
171,000
| – | – | 0.06% | 353 |
|
|
2018
Q2 | $4.69M | Hold |
171,000
| – | – | 0.07% | 306 |
|
|
2018
Q1 | $5.27M | Buy |
171,000
+20,000
| +13% | +$644K | 0.09% | 273 |
|
|
2017
Q4 | $5.4M | Buy |
151,000
+15,000
| +11% | +$431K | 0.09% | 259 |
|
|
2017
Q3 | $3.75M | Sell |
136,000
-4,000
| -3% | -$97K | 0.07% | 329 |
|
|
2017
Q2 | $3.7M | Buy |
140,000
+18,000
| +15% | +$401K | 0.07% | 333 |
|
|
2017
Q1 | $2.54M | Buy |
122,000
+55,000
| +82% | +$1.13M | 0.05% | 397 |
|
|
2016
Q4 | $1.39M | Buy |
+67,000
| New | +$1.12M | 0.03% | 449 |
|
Other funds holding RVNC
Candriam SCA's RVNC Position: Q1 2025 in Review
Candriam SCA sold out of Revance Therapeutics, Inc. (RVNC) in Q1 2025, closing a stake of 299,039 shares — an estimated $909K sold.
Candriam SCA first reported a position in RVNC in Q4 2016 and held it in 16 quarters. The position peaked at $5.4M in Q4 2017. 1 fund tracked by Wall St. Rank holds RVNC as of Q1 2025.
- Candriam SCA reported no remaining Revance Therapeutics, Inc. position as of Q1 2025 after selling out during the quarter.
- Candriam SCA sold 299,039 Revance Therapeutics, Inc. shares in Q1 2025, an estimated $909K.
- Candriam SCA first reported a position in Revance Therapeutics, Inc. in Q4 2016 and held it in 16 quarters.
- Candriam SCA's Revance Therapeutics, Inc. position peaked at $5.4M in Q4 2017.
- 1 fund tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q1 2025.
Based on Candriam SCA's 13F filing for Q1 2025, filed 14 May 2025.